Drug Trial Radar · NCT06901531
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Sep 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive). Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. Certain stomach and GEJ cancers may be treated with immunotherapy, which helps the body's immune system fight cancer. This study will give more information about how well zolbetuximab works when given with an immunotherapy medicine called pembrolizumab and chemotherapy. In this study, adults with stomach cancer or GEJ cancer will either be given zolbetuximab with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. The main aim of the study is to check how long people with stomach cancer and GEJ cancer live after treatment with zolbetuximab with pembrolizumab and chemotherapy compared to placebo with pembrolizumab and chemotherapy. Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample (biopsy) of their cancer will have the Claudin 18.2 protein, PD-L1 protein, and be HER2-negative. They may have been previously treated with certain standard therapies. People can also take part if they need to take medicines like steroids to suppress their immune system. They cannot take part if they have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections. The study treatments are either zolbetuximab with pembrolizumab and chemotherapy, or placebo with pembrolizumab and chemotherapy. People who take part will receive just 1 of the study treatments by chance. The people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in 6-week (42-day) cycles. The study treatment is mainly given to people slowly through a tube into a vein. This is called an infusion. People will receive study treatment as follows: Zolbetuximab or placebo: 1 infusion every 2 or 3 weeks (2 or 3 infusions in a cycle) together with: Chemotherapy (1 of the following types of chemotherapy): 1. CAPOX (capecitabine and oxaliplatin): 1 infusion of oxaliplatin every 3 weeks (2 infusions in a cycle). People will also take 1 tablet of capecitabine twice a day for 2 weeks (14 days) at the start of each cycle (Day 1) and again in the middle of each cycle (Day 22). After 8 study treatments people will receive capecitabine only. 2. Modified FOLFOX6 or mFOLFOX6 (5-fluorouracil, folinic acid and oxaliplatin): 1 infusion every 2 weeks (3 infusions in a cycle). After 12 study treatments people will receive folinic acid and fluorouracil only, instead of mFOLFOX6. Pembrolizumab: 1 infusion every 3 or 6 weeks (1 or 2 infusions in a cycle). People can be in the study and will receive study treatment until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People may receive pembrolizumab for up to 2 years. People will visit the clinic on certain days to receive their study treatment and have health checks. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample if they stop treatment because their cancer has worsened. People will visit the clinic after they stop their study treatment. People will be asked about any medical problems and will have a health check. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. They will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.
Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- Metastatic Gastric Adenocarcinoma or Cancer
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximabDrug
Participants will receive an IV infusion of zolbetuximab on Cycle 1 Day 1 (C1D1) followed by subsequent IV infusion every 2 weeks or every 3 weeks.
PembrolizumabDrug
Participants will receive an IV infusion of pembrolizumab every 3 weeks or every 6 weeks.
CapecitabineDrug
Participants receiving CAPOX regimen of chemotherapy will receive capecitabine Tablet twice daily orally on days 1 through 14 and days 22 through 35 of each cycle.
OxaliplatinDrug
Participants receiving CAPOX or mFOLFOX6 regimen of chemotherapy will receive an IV infusion of oxaliplatin once every 2 or 3 weeks.
Folinic acid (leucovorin or local equivalent)Drug
Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of Folinic acid (leucovorin or local equivalent) once every 2 weeks.
5-fluorouracil (5-FU)Drug
Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion, or IV bolus of 5-FU once every 2 weeks.
PlaceboDrug
Participants will receive an IV infusion of placebo (0.9% of sodium chloride) on C1D1 followed by subsequent IV infusion every 2 weeks or every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 72 months
Locations
253 sites in 22 countries. Site status is shown where the registry gives one.
UAB Medicine - UAB Hospital
Birmingham, Alabama · Withdrawn
CBCC Global Research - Comprehensive Blood & Cancer Center
Bakersfield, California · Recruiting
TOI Clinical Research
Cerritos, California · Recruiting
University of California, San Diego Moores Cancer Center
La Jolla, California · Recruiting
The Angeles Clinic and Research Institute, West Los Angeles Office
Los Angeles, California · Recruiting
Hartford HealthCare - Hartford Hospital
Hartford, Connecticut · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Piedmont Physician Medical Oncology Atlanta
Atlanta, Georgia · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Franciscan Health Oncology and Hematology Specialists
Indianapolis, Indiana · Recruiting
Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Saint Elizabeth Medical Center Edgewood
Edgewood, Kentucky · Recruiting
University of Maryland Medical System - University of Maryland Medical Center
Baltimore, Maryland · Recruiting
Dana Farber/Harvard Cancer Center
Boston, Massachusetts · Recruiting
University of Massachusetts - UMass Chan Medical School
Worcester, Massachusetts · Recruiting
University of Michigan Health System
Ann Arbor, Michigan · Recruiting
Barbara Ann Karmanos Cancer Center
Detroit, Michigan · Recruiting
Henry Ford Cancer Institute-Henry Ford Hospital
Detroit, Michigan · Recruiting
Metro Minnesota Community Oncology Research Consortium (MMCORC)
Saint Louis Park, Minnesota · Recruiting
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Withdrawn
Capital Health - Hematology Oncology Specialists
Pennington, New Jersey · Recruiting
NYU Langone Medical Center
New York, New York · Recruiting
Stony Brook University Hospital Cancer Center
Stony Brook, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Duke University Medical Center - Duke Cancer Centre
Durham, North Carolina · Recruiting
Allegheny General Hospital (AGH)-Allegheny Singer Research Institute
Pittsburgh, Pennsylvania · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
The University of Tennessee Medical Center
Knoxville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Texas Oncology-Baylor Charles A Sammons Cancer Center
Dallas, Texas · Recruiting
The Center For Cancer And Blood Disorders (Texas Cancer Care)
Fort Worth, Texas · Recruiting
Houston Methodist Cancer Center
Houston, Texas · Recruiting
Utah Cancer Specialists Cancer Center - Medical Oncology
Salt Lake City, Utah · Recruiting
Inova Schar Cancer Institute Clinical Trials
Fairfax, Virginia · Recruiting
Site AU61001
Fitzroy, Australia · Recruiting
Site AU61002
Kogarah, New South Wales, Australia · Recruiting
Showing 40 of 253 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.